Cargando…

Elevated Anti-Müllerian Hormone Is an Independent Risk Factor for Preterm Birth Among Patients With Overweight Polycystic Ovary Syndrome

OBJECTIVE: To explore whether elevated anti-Müllerian hormone (AMH) levels affect the rate of preterm birth (PTB) among PCOS patients with different BMIs. METHODS: In this retrospective cohort study, patients with PCOS who had undergone IVF/ICSI from January 2017 to December 2019 were included for p...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Mingze, Zhang, Junwei, Yu, Xiaona, Guan, Yichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692368/
https://www.ncbi.nlm.nih.gov/pubmed/34956097
http://dx.doi.org/10.3389/fendo.2021.788000
_version_ 1784618942172495872
author Du, Mingze
Zhang, Junwei
Yu, Xiaona
Guan, Yichun
author_facet Du, Mingze
Zhang, Junwei
Yu, Xiaona
Guan, Yichun
author_sort Du, Mingze
collection PubMed
description OBJECTIVE: To explore whether elevated anti-Müllerian hormone (AMH) levels affect the rate of preterm birth (PTB) among PCOS patients with different BMIs. METHODS: In this retrospective cohort study, patients with PCOS who had undergone IVF/ICSI from January 2017 to December 2019 were included for potential evaluation. A total of 2368 singleton live births from PCOS patients were included. According to the BMI, all the PCOS patients were divided into two groups: BMI<24 kg/m(2) and BMI≥24 kg/m(2). In total, 1339 PCOS patients with a BMI<24 kg/m(2) were grouped according to their serum AMH levels: ① <2.71 ng/ml (n=333), ② 2.71-4.08 ng/ml (n=330), ③ 4.09-6.45 ng/ml (n=351), and ④ >6.45 ng/ml (n=325). Additionally, 1029 cycles of patients with a BMI≥24 kg/m(2) were grouped according to the serum AMH level: ① <2.71 ng/ml (n=255), ② 2.71-4.08 ng/ml (n=267), ③ 4.09-6.45 ng/ml (n=239), and ④ >6.45 ng/ml (n=268), with <2.71 ng/ml being considered the reference group. The grouping was based mainly on the interquartile range of serum AMH levels. The primary outcome of the study was PTB. The secondary outcomes were low birth weight (LBW), small for gestational age (SGA), macrosomia and large for gestational age (LGA). RESULTS: Regarding PCOS patients with a BMI<24 kg/m(2), compared with the PTB rate of the AMH <2.71 ng/ml group, the PTB rates of the different groups were not significantly different (AMH 2.71-4.08, AOR (95% CI)=1.01 (0.52-2.00), P=0.99; AMH 4.09-6.45, AOR (95% CI)=0.93 (0.45-1.91), P=0.85; AMH>6.45, AOR (95% CI)=0.78 (0.35-1.73), P=0.54). Regarding PCOS patients with a BMI ≥24 kg/m(2), compared with the PTB rate of the AMH <2.71 ng/ml group, the PTB rate of the AMH>6.45 ng/ml group was significantly higher (OR=2.47; 95% CI=1.34-4.55). After multiple logistic regression analysis, the risk of PTB in the AMH>6.45 ng/ml group was 2.1 times that in the AMH<2.71 ng/ml group (AOR=2.1, 95% CI=1.01-4.37, P=0.04). However, no statistically significant difference was found in the rate of SGA, LBW, macrosomia or LGA among patients in the different serum AMH groups. CONCLUSION: For PCOS patients, a BMI≥24 kg/m(2) plus serum AMH>6.45 ng/ml (75th percentile) is an independent risk factor for PTB.
format Online
Article
Text
id pubmed-8692368
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86923682021-12-23 Elevated Anti-Müllerian Hormone Is an Independent Risk Factor for Preterm Birth Among Patients With Overweight Polycystic Ovary Syndrome Du, Mingze Zhang, Junwei Yu, Xiaona Guan, Yichun Front Endocrinol (Lausanne) Endocrinology OBJECTIVE: To explore whether elevated anti-Müllerian hormone (AMH) levels affect the rate of preterm birth (PTB) among PCOS patients with different BMIs. METHODS: In this retrospective cohort study, patients with PCOS who had undergone IVF/ICSI from January 2017 to December 2019 were included for potential evaluation. A total of 2368 singleton live births from PCOS patients were included. According to the BMI, all the PCOS patients were divided into two groups: BMI<24 kg/m(2) and BMI≥24 kg/m(2). In total, 1339 PCOS patients with a BMI<24 kg/m(2) were grouped according to their serum AMH levels: ① <2.71 ng/ml (n=333), ② 2.71-4.08 ng/ml (n=330), ③ 4.09-6.45 ng/ml (n=351), and ④ >6.45 ng/ml (n=325). Additionally, 1029 cycles of patients with a BMI≥24 kg/m(2) were grouped according to the serum AMH level: ① <2.71 ng/ml (n=255), ② 2.71-4.08 ng/ml (n=267), ③ 4.09-6.45 ng/ml (n=239), and ④ >6.45 ng/ml (n=268), with <2.71 ng/ml being considered the reference group. The grouping was based mainly on the interquartile range of serum AMH levels. The primary outcome of the study was PTB. The secondary outcomes were low birth weight (LBW), small for gestational age (SGA), macrosomia and large for gestational age (LGA). RESULTS: Regarding PCOS patients with a BMI<24 kg/m(2), compared with the PTB rate of the AMH <2.71 ng/ml group, the PTB rates of the different groups were not significantly different (AMH 2.71-4.08, AOR (95% CI)=1.01 (0.52-2.00), P=0.99; AMH 4.09-6.45, AOR (95% CI)=0.93 (0.45-1.91), P=0.85; AMH>6.45, AOR (95% CI)=0.78 (0.35-1.73), P=0.54). Regarding PCOS patients with a BMI ≥24 kg/m(2), compared with the PTB rate of the AMH <2.71 ng/ml group, the PTB rate of the AMH>6.45 ng/ml group was significantly higher (OR=2.47; 95% CI=1.34-4.55). After multiple logistic regression analysis, the risk of PTB in the AMH>6.45 ng/ml group was 2.1 times that in the AMH<2.71 ng/ml group (AOR=2.1, 95% CI=1.01-4.37, P=0.04). However, no statistically significant difference was found in the rate of SGA, LBW, macrosomia or LGA among patients in the different serum AMH groups. CONCLUSION: For PCOS patients, a BMI≥24 kg/m(2) plus serum AMH>6.45 ng/ml (75th percentile) is an independent risk factor for PTB. Frontiers Media S.A. 2021-12-08 /pmc/articles/PMC8692368/ /pubmed/34956097 http://dx.doi.org/10.3389/fendo.2021.788000 Text en Copyright © 2021 Du, Zhang, Yu and Guan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Du, Mingze
Zhang, Junwei
Yu, Xiaona
Guan, Yichun
Elevated Anti-Müllerian Hormone Is an Independent Risk Factor for Preterm Birth Among Patients With Overweight Polycystic Ovary Syndrome
title Elevated Anti-Müllerian Hormone Is an Independent Risk Factor for Preterm Birth Among Patients With Overweight Polycystic Ovary Syndrome
title_full Elevated Anti-Müllerian Hormone Is an Independent Risk Factor for Preterm Birth Among Patients With Overweight Polycystic Ovary Syndrome
title_fullStr Elevated Anti-Müllerian Hormone Is an Independent Risk Factor for Preterm Birth Among Patients With Overweight Polycystic Ovary Syndrome
title_full_unstemmed Elevated Anti-Müllerian Hormone Is an Independent Risk Factor for Preterm Birth Among Patients With Overweight Polycystic Ovary Syndrome
title_short Elevated Anti-Müllerian Hormone Is an Independent Risk Factor for Preterm Birth Among Patients With Overweight Polycystic Ovary Syndrome
title_sort elevated anti-müllerian hormone is an independent risk factor for preterm birth among patients with overweight polycystic ovary syndrome
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692368/
https://www.ncbi.nlm.nih.gov/pubmed/34956097
http://dx.doi.org/10.3389/fendo.2021.788000
work_keys_str_mv AT dumingze elevatedantimullerianhormoneisanindependentriskfactorforpretermbirthamongpatientswithoverweightpolycysticovarysyndrome
AT zhangjunwei elevatedantimullerianhormoneisanindependentriskfactorforpretermbirthamongpatientswithoverweightpolycysticovarysyndrome
AT yuxiaona elevatedantimullerianhormoneisanindependentriskfactorforpretermbirthamongpatientswithoverweightpolycysticovarysyndrome
AT guanyichun elevatedantimullerianhormoneisanindependentriskfactorforpretermbirthamongpatientswithoverweightpolycysticovarysyndrome